Status:

COMPLETED

Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease

Lead Sponsor:

Xtant Medical

Conditions:

Degenerative Disc Disease

Eligibility:

All Genders

18+ years

Brief Summary

This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology.

Detailed Description

This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology....

Eligibility Criteria

Inclusion

  • The subject is skeletally mature and at least 18 years of age.
  • The subject has degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptom at one or two contiguous levels (Fortilink-C), or the subject has DDD and ≤ Grade 1 spondylolisthesis of the lumbar spine at one or two contiguous levels (Fortilink-TS and Fortilink-L).
  • Subject plans to undergo one of the following procedures:
  • An anterior cervical interbody fusion at one to two continuous levels from C2-C3 to C7-T1 using autogenous or allogenic bone graft and supplemental fixation cleared and indicated for use at the proposed treatment level(s) (Fortilink-C), or
  • An interbody fusion in the lumbar spine at one to two continuous levels from L1-L2 to L5-S1 using autogenous or allogenic bone graft and supplemental fixation cleared and indicated for use at the proposed treatment level(s) (Fortilink-TS and Fortilink-L).
  • The subject has undergone non-operative treatment of at least six weeks (Fortilink-C) or at least six months (Fortilink-TS and Fortilink-L) prior to treatment with the IBF system.
  • The subject is willing and able to provide informed consent.
  • The subject is willing and able to attend the protocol required follow-up visits and examinations.

Exclusion

  • The subject has an active infection
  • The subject has had prior fusion attempt(s) or is undergoing revision of a previously implanted system at the involved level(s).
  • The subject is a worker's compensation case, in active litigation related to the procedure or is a prisoner or ward of the state.
  • The subject meets one or more of the contraindications outlined in the IFU.
  • The subject is pregnant, nursing, or is planning to become pregnant in the next year.
  • The subject has documented evidence of current substance abuse.
  • The subject has other concurrent medical condition that, in the opinion of the investigator, does not make the subject a good candidate for the study.

Key Trial Info

Start Date :

February 13 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 30 2023

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT03761563

Start Date

February 13 2019

End Date

December 30 2023

Last Update

March 15 2024

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Los Angeles Orthopedic Institute

Sherman Oaks, California, United States, 91403

2

Rocky Mountain Spine Clinic

Lone Tree, Colorado, United States, 80124

3

Florida Back Institute

Boca Raton, Florida, United States, 33496

4

South Florida Spine & Orthopaedics

Coconut Creek, Florida, United States, 33073